For most of the last decade, Medicare Advantage growth covered a lot of operational sins. Rates rose, enrollment climbed, and a plan could carry a mediocre Star Rating without feeling it in the margin. That era is over. With the final 2027 rate set against medical costs that have run hot across the industry, the gap between a 3.5-star plan and a 4-star plan is no longer a quality-department talking point. It is a line on the income statement. Quality bonus dollars have quietly become one of the few margin levers a plan still controls, and most plans are underusing it.
The 2027 rate reality
CMS finalized a net effective growth rate of about 2.48 percent for 2027, which the agency estimates as an increase of more than $13 billion in payments to plans. With expected growth in risk scores, CMS projects the average change at roughly 4.98 percent, or about $26 billion. The headline 2.48 percent came in well above the 0.09 percent CMS had floated in the January advance notice, so on paper the final number looks like relief.
It is not relief. Two things take the shine off. First, the 2027 figure sits below the prior year: CY2026 landed at roughly 5.06 percent. So even the better-than-proposed 2027 rate is a step down from the year before. Second, the average is just that, an average. The risk-score component that lifts the number to 4.98 percent does not arrive evenly. A plan’s actual revenue change depends on its own risk profile, its coding accuracy, and its book of business, and plenty of plans will see something well under the cheerful average.
The risk-adjustment squeeze
Underneath the topline rate, CMS tightened the way diagnoses turn into dollars. The agency finalized a policy that excludes certain diagnoses sourced only from chart reviews that are not linked to a confirmed clinical encounter, with a limited exception for members who switch plans. The intent is to stop paying for diagnoses that exist on paper but not in a visit, and CMS projects the change will reduce aggregate payments through the sources-of-diagnoses adjustment.
Layer that on top of the risk model transition that has been phasing in over recent payment years, and the direction is consistent: CMS is squeezing revenue per member toward documented, clinically supported care and away from coding intensity. For a plan that built its margin on aggressive risk capture, that is a structural headwind, not a one-year dip. For a plan that built its margin on actual clinical performance, it is closer to neutral, and that distinction is exactly the point of where the program is heading.
The scissor
Put the two blades together. On one side, revenue growth is capped, stepped down from last year, and tilted toward documented care. On the other side, medical cost trends have run high across the industry, with utilization and unit costs both pressing upward. Revenue held down, costs pushed up: that is a scissor closing on the margin, and it closes hardest on the plans with the least cushion.
And the cushion is thin by design. Medicare Advantage plans must spend at least 85 percent of premium on medical care under the medical loss ratio rule, which leaves a narrow band for administration and margin. When that narrow band has to absorb a rising cost trend against a capped top line, there is very little slack to give. A few points of rating-driven revenue can be the difference between a contract that clears its targets and one that does not.
When the top line cannot save you and costs will not relent, attention turns to the levers a plan still controls. There are not many. Network and utilization management is one. Administrative efficiency is another. And then there is the lever that sits, oddly, inside the quality department: the Star Rating, and the bonus dollars attached to it.
How quality dollars actually flow
This is the part that finance often understands better than quality, and quality often understands better than finance, which is precisely why the two functions need to be in the same room.
Two mechanisms turn stars into money. The first is the quality bonus payment. Contracts rated 4 stars or higher earn a 5 percent bonus added to their county benchmark, the figure that anchors what CMS pays. A plan that falls from 4 stars to 3.5 does not just lose bragging rights. It loses that benchmark bonus across its entire membership in the affected contract.
The second is the rebate. When a plan bids below its benchmark, it keeps a share of the difference as a rebate, which it must spend on supplemental benefits, the dental, vision, over-the-counter, and reduced cost-sharing that make a plan competitive at the point of sale. The share a plan keeps rises with its Star Rating, from roughly half at the low end up to 70 percent for the highest-rated plans, with the step-ups tied to Star thresholds. So a higher rating does double duty: it adds the benchmark bonus and it lets the plan keep more of its savings to fund the benefits that drive enrollment. Lose the rating and both shrink at once, which means thinner benefits, a less competitive product, and slower growth, on top of the direct payment hit.
The clinical measures that drive those stars are, in large part, NCQA’s HEDIS measures and the survey and outcome measures alongside them. The quality work and the revenue are the same work, viewed from two ends of the building.
What it means for a value-based provider group
If you are a Chief Medical Officer or medical director on the provider side of a value-based contract, none of this is abstract, because the plan’s Star economics flow downhill to you. The bonus and rebate dollars a plan earns from a strong rating are part of what funds the shared-savings pools and quality incentives in your agreement. When the plan’s rating slips, the pool it can offer shrinks, and the measures it leans on you to move are exactly the clinical and outcome measures that now carry the most weight. Your panel produces the screenings, the controlled blood pressures, the depression follow-ups. The plan reports them. The rating, and the dollars, depend on both halves working. A provider group that knows which measures carry the most dollars per point can steer its own clinical effort toward the work that is both good medicine and good economics, instead of chasing whatever lands on the gap report that month.
The math of a half star
Make it concrete, with the arithmetic kept deliberately simple. Picture a contract with a meaningful membership base and a per-member benchmark in the normal Medicare Advantage range. The 5 percent quality bonus on that benchmark, multiplied across every member for a full year, is not a rounding error. It is a number with a comma in it that most finance teams would fight hard to protect anywhere else in the business. Add the rebate difference, the extra share of savings a 4-star plan keeps versus a 3.5-star plan, and the gap between those two ratings can be the difference between funding a competitive benefit package and cutting one.
That is why a half star is balance-sheet relevant in 2027 in a way it was not when rates were climbing 5 and 6 percent a year. When growth covered the gap, a soft rating was survivable. With the scissor closing, the bonus dollars are part of how a plan stays whole.
A stabilizing field raises the bar
After a few years of volatility, the 2026 Star Ratings settled onto steadier ground. That sounds reassuring, and for the program it is. For an individual plan it is a warning. Stability at the top means more contracts clustering near and above 4 stars, and because cut points are relative, a crowded field pushes the threshold for the bonus higher. Holding a 4-star rating in a field where everyone is improving takes more real performance each year than it did the year before. The bonus dollars do not get easier to earn as the program matures. They get harder, which is one more reason to treat them as something you actively defend rather than assume you will keep.
Why this is a data problem before it is a quality problem
Here is the move most plans miss. If a half star is worth that much, then the few measures sitting closest to a cut-point boundary, the bubble measures, are among the highest-return work in the entire company, not just the quality department. A heavily weighted measure parked just below a star threshold is a lever with a dollar figure attached, and moving it is worth more than most discretionary spend a plan considers.
But you cannot manage what you cannot see. Knowing which measures are on the bubble, how far they sit from the threshold, which members are driving the gap, and what it would take to close it, is a data problem. It requires precision about cut points that move every year, traceability from a reported rate down to the members and the source records behind it, and the ability to tell a real performance gap from a data-capture artifact. A plan that treats its rating as an annual surprise, delivered by CMS each October, is leaving the single most controllable margin lever to chance. And chance, in a tight-margin year, is not a strategy a board will accept twice.
What to do with this
Three moves, and the first is cultural.
First, treat the Star Rating as a revenue line, not a compliance function. Put it on the same page as the financial forecast, with a dollar value attached to each plausible rating outcome. A rating projection that does not carry a dollar figure is not finished.
Second, fund the bubble. Identify the heavily weighted measures closest to a threshold, attach the bonus-and-rebate dollars at stake to each one, and prioritize improvement spend by return, the same way you would any capital allocation. The measure with the highest dollars-per-point should be first in line, not the measure that is easiest to talk about.
Third, get finance and quality into one model. The quality team knows where the measures sit. Finance knows what a half star is worth. Neither can size the opportunity alone, and the plans that close the gap between those two views are the ones that will defend their margin while the scissor keeps closing.
And put a defensible number on it before you ask for anything. When you walk into the budget meeting, the ask should not be “we need funding for quality improvement.” It should be “this measure is worth this much in bonus and rebate dollars at risk, here is the cost to move it, and here is the return.” Framed that way, Star improvement competes for capital on the same terms as everything else in the business, and it usually wins.
The honest version
A plan can spend a whole year improving care and still lose the bonus dollars if it improved the wrong measures, or if its data understated the measures it actually moved. In a year when growth no longer covers mistakes, that is an expensive way to find out your numbers were soft. The plans that come through 2027 with their margins intact will be the ones that can see, precisely and in dollars, where their rating stands and what it would take to move it, traced from the star back to the member and the record. That clarity is not a quality nicety. It is margin protection, and we think it should be visible enough to take to the board. Precision is not a luxury when the margin is this tight. It is the cheapest revenue a plan can find, because it is revenue you have already earned and only have to prove. Proving it, precisely, is the job.
HEDIS is a registered trademark of the National Committee for Quality Assurance.